Your SlideShare is downloading. ×
0
Lung Cancer: an overview & discussion of  minimally invasive surgical therapy Conrad Massimo Vial, MD Director of Cardioth...
 
 
 
 
 
 
Tumor T1 T2 T3 T4 Nodes N0 N1 N2 N3 IA IB IIB IIIB Stage IV = M1 Stage IIIB and IV generally unresectable Lung Cancer IIIB...
5-yr survival for treated NSCLC according to surg-path state: Stage I:  ≈ 70% Stage II:  ≈ 50% Stage III:  ≈ 20%
Minimally Invasive Lung Cancer Operations Video Assisted Thoracoscopic (VATS) Lobectomy &  Lung Sparing Operations
The Traditional Approach Open Thoracotomy
Video Assisted Thoracoscopy (VATS)
VATS Lobectomy
 
 
Results in the Literature <ul><li>Advantages of VATS Approach . . . </li></ul><ul><ul><li>Less postoperative pain </li></u...
Literature Summary <ul><li>VATS lobectomy offers advantages over conventional thoracotomy without compromise of short term...
Lung Sparing Operations Bronchoplasties & Sleeve Resections
Definition of Bronchoplastic Techniques <ul><li>Sleeve Lobectomy </li></ul><ul><li>vs </li></ul><ul><li>Bronchial Sleeve R...
 
 
Results in the Literature <ul><li>30 day mortality for all bronchoplastic procedures is 8% </li></ul><ul><li>Mortality for...
What are we doing? What are our results? Conrad M Vial, MD Tomomi Oka, MD
Program in CT Surgery  Overall Volume & Outcomes 2008-2010 TOTAL CASES = 1216 MORTALITY = 0.7% MAJOR MORBIDITY = 3.9% CARD...
Diversity & Complexity of  Major Thoracic Operations
Diversity & Complexity of  Major Thoracic Lung Operations Bronchoplasty and/or Sleeve Resection n=15 Thoracoscopic Lobecto...
STS NATIONAL DATABASE Influence of Functional Score in Resections for Lung Cancer ZUBROD SCORE MORTALITY LOS > 14 DAYS COM...
STS NATIONAL DATABASE Influence of FEV 1  in Resections for Lung Cancer Preop FEV 1 MORTALITY LOS > 14 DAYS COMPLICATIONS ...
Diversity & Complexity of  Major Thoracic Operations for Lung Ca Bronchoplasty and/or Sleeve Resection n=15 Thoracoscopic ...
CRUDE Benchmarking “Best Case” vs Non-risk adjusted Best Case Lung Ca Resection STS Scenario Mortality LOS  > 14 days Comp...
THANK YOU !
Upcoming SlideShare
Loading in...5
×

Lung Cancer: An Overview & Discussion of Minimally Invasive Surgical Therapy

1,998

Published on

Presentation of "Lung Cancer: An Overview & Discussion of Minimally Invasive Surgical Therapy," by Dr. Conrad Vial, Director of Cardiothoracic Surgery, Mills-Peninsula Health Services.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,998
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
171
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Lung Cancer: An Overview & Discussion of Minimally Invasive Surgical Therapy"

  1. 1. Lung Cancer: an overview & discussion of minimally invasive surgical therapy Conrad Massimo Vial, MD Director of Cardiothoracic Surgery Mills Peninsula Health System
  2. 8. Tumor T1 T2 T3 T4 Nodes N0 N1 N2 N3 IA IB IIB IIIB Stage IV = M1 Stage IIIB and IV generally unresectable Lung Cancer IIIB IIIB IIIB IIIB IIIA IIIA IIIA IIIB IIA IIB IIIA IIIB
  3. 9. 5-yr survival for treated NSCLC according to surg-path state: Stage I: ≈ 70% Stage II: ≈ 50% Stage III: ≈ 20%
  4. 10. Minimally Invasive Lung Cancer Operations Video Assisted Thoracoscopic (VATS) Lobectomy & Lung Sparing Operations
  5. 11. The Traditional Approach Open Thoracotomy
  6. 12. Video Assisted Thoracoscopy (VATS)
  7. 13. VATS Lobectomy
  8. 16. Results in the Literature <ul><li>Advantages of VATS Approach . . . </li></ul><ul><ul><li>Less postoperative pain </li></ul></ul><ul><ul><li>Shorter length of stay </li></ul></ul><ul><ul><ul><li>Reduced air leaks/length of chest tube placement </li></ul></ul></ul><ul><ul><ul><li>Reduced overall hospital cost </li></ul></ul></ul><ul><ul><li>Faster recovery/return to normal activities </li></ul></ul><ul><ul><li>Better postoperative pulmonary function </li></ul></ul><ul><ul><li>More likely to complete postoperative chemotherapy </li></ul></ul>
  9. 17. Literature Summary <ul><li>VATS lobectomy offers advantages over conventional thoracotomy without compromise of short term or long term outcome </li></ul><ul><li>VATS lobectomy can become a cost effective alternative to open lobectomy in the treatment of operable NSCLC </li></ul>
  10. 18. Lung Sparing Operations Bronchoplasties & Sleeve Resections
  11. 19. Definition of Bronchoplastic Techniques <ul><li>Sleeve Lobectomy </li></ul><ul><li>vs </li></ul><ul><li>Bronchial Sleeve Resection </li></ul>A A
  12. 22. Results in the Literature <ul><li>30 day mortality for all bronchoplastic procedures is 8% </li></ul><ul><li>Mortality for sleeve lobectomy is 5% </li></ul><ul><li>Mortality for sleeve pneumonectomy is 20 – 25% </li></ul><ul><li>Mortality rates double or triple in the presence of; </li></ul><ul><ul><li>Poor pulmonary function (FEV 1 < 50% predicted) </li></ul></ul><ul><ul><li>Pulmonary hypertension </li></ul></ul><ul><ul><li>Severe coronary artery disease </li></ul></ul>
  13. 23. What are we doing? What are our results? Conrad M Vial, MD Tomomi Oka, MD
  14. 24. Program in CT Surgery Overall Volume & Outcomes 2008-2010 TOTAL CASES = 1216 MORTALITY = 0.7% MAJOR MORBIDITY = 3.9% CARDIAC CASES = 529 MORTALITY = 1.5% MAJOR MORBIDITY = 6.2% THORACIC CASES = 687 MORTALITY = 0.4% MAJOR MORBIDITY = 2.8%
  15. 25. Diversity & Complexity of Major Thoracic Operations
  16. 26. Diversity & Complexity of Major Thoracic Lung Operations Bronchoplasty and/or Sleeve Resection n=15 Thoracoscopic Lobectomy n=107
  17. 27. STS NATIONAL DATABASE Influence of Functional Score in Resections for Lung Cancer ZUBROD SCORE MORTALITY LOS > 14 DAYS COMPLICATIONS 0 1.3% 4.8% 32% 1 1.8% 6.8% 35% 2 3.5% 12% 41% 3 7% 14% 46% 4 16% 21% 51%
  18. 28. STS NATIONAL DATABASE Influence of FEV 1 in Resections for Lung Cancer Preop FEV 1 MORTALITY LOS > 14 DAYS COMPLICATIONS > 80% pred 1.1% 4% 30% 61-79% pred 2% 8% 39% < 60% pred 2% 9% 41%
  19. 29. Diversity & Complexity of Major Thoracic Operations for Lung Ca Bronchoplasty and/or Sleeve Resection n=15 Thoracoscopic Lobectomy n=107
  20. 30. CRUDE Benchmarking “Best Case” vs Non-risk adjusted Best Case Lung Ca Resection STS Scenario Mortality LOS > 14 days Complications Preop FEV 1 > 80% pred & Zubrod Score 0 ~1.2% ~4% ~30%
  21. 31. THANK YOU !
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×